Literature DB >> 8740913

Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis.

A Colley1, D Donnai, D G Evans.   

Abstract

Since January 1989 we have ascertained patients with neurofibromatosis type 1 (NF1) as part of our genetic register in the North West of England. This register has now identified 453 affected cases from 235 families. The first 94 individuals were specifically examined for features of the Noonan phenotype. This was present in 12/94 sequentially identified individuals with NF1 including six individuals from three families. However, three cases occurred in a further family, where Noonan syndrome appeared to segregate separately from NF1. We have provided evidence for the chance association of Noonan syndrome and NF1 and that the Noonan phenotype occurs as a feature in some NF1 families. However, there is now little evidence of a separate NF1/Noonan syndrome entity or of NF1 features occurring in classical Noonan syndrome.

Entities:  

Mesh:

Year:  1996        PMID: 8740913     DOI: 10.1111/j.1399-0004.1996.tb04328.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

1.  Familial neurofibromatosis type 1 associated with an overgrowth syndrome resembling Weaver syndrome.

Authors:  C J van Asperen; W C Overweg-Plandsoen; M H Cnossen; D A van Tijn; R C Hennekam
Journal:  J Med Genet       Date:  1998-04       Impact factor: 6.318

2.  Cherubism associated with neurofibromatosis type 1, and multiple osteolytic lesions of both femurs: a previously undescribed association of findings.

Authors:  Francisco J Martínez-Tello; Palmira Manjón-Luengo; Manuel Martin-Pérez; Santiago Montes-Moreno
Journal:  Skeletal Radiol       Date:  2005-08-11       Impact factor: 2.199

3.  Next-generation sequencing identifies rare variants associated with Noonan syndrome.

Authors:  Peng-Chieh Chen; Jiani Yin; Hui-Wen Yu; Tao Yuan; Minerva Fernandez; Christina K Yung; Quang M Trinh; Vanya D Peltekova; Jeffrey G Reid; Erica Tworog-Dube; Margaret B Morgan; Donna M Muzny; Lincoln Stein; John D McPherson; Amy E Roberts; Richard A Gibbs; Benjamin G Neel; Raju Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

4.  Syndromic Hearing Loss in Association with PTPN11-Related Disorder: The Experience of Cochlear Implantation in a Child with LEOPARD Syndrome.

Authors:  Ho-Suk Chu; Hae-Sun Chung; Moon-Hee Ko; Hee-Jin Kim; Chang-Seok Ki; Won-Ho Chung; Yang-Sun Cho; Sung Hwa Hong
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-02-07       Impact factor: 3.372

5.  Neurofibromatosis Type 1 Presenting with Ophthalmic Features: A Case Series.

Authors:  Gunjan Jain; Vaibhav Kumar Jain; Indra Kumar Sharma; Reena Sharma; Neeraj Saraswat
Journal:  J Clin Diagn Res       Date:  2016-11-01

6.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

7.  Neurofibromatosis type 1 (NF1) associated with tumor of the corpus callosum.

Authors:  Ignacio Pascual-Castroviejo; Samuel-Ignacio Pascual-Pascual
Journal:  Childs Nerv Syst       Date:  2012-09-22       Impact factor: 1.475

8.  Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype.

Authors:  D A Stevenson; D H Viskochil; A F Rope; J C Carey
Journal:  Clin Genet       Date:  2006-03       Impact factor: 4.438

9.  Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients.

Authors:  V M Park; E K Pivnick
Journal:  J Med Genet       Date:  1998-10       Impact factor: 6.318

Review 10.  Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature.

Authors:  K A Mensink; R P Ketterling; H C Flynn; R A Knudson; N M Lindor; B A Heese; R J Spinner; D Babovic-Vuksanovic
Journal:  J Med Genet       Date:  2006-02       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.